Literature DB >> 27134825

MELAS syndrome due to the m.3291T > C mutation.

Josef Finsterer1, Sinda Zarrouk-Mahjoub2.   

Abstract

Entities:  

Keywords:  Cardiac involvement; Cerebral MRI; Epilepsy; Mitochondrial DNA; Multisystem disease; Stroke-like episodes

Year:  2016        PMID: 27134825      PMCID: PMC4834681          DOI: 10.1016/j.ymgmr.2016.03.011

Source DB:  PubMed          Journal:  Mol Genet Metab Rep        ISSN: 2214-4269


× No keyword cloud information.
Dear Editor: With interest we read the article by Keilland et al. about a 12 yo female with MELAS-syndrome due to the m.3291T > C mutation, manifesting as overlap between MELAS, MERRF, MNGIE, KSS, and CPEO [1]. We have the following comments and concerns. Apparently, the m.3291T > C mutation does not manifest significantly in the heart [1]. Did the propositus undergo comprehensive cardiologic investigations, including echocardiography and long-term ECG-recordings? Hypertrophic and dilated cardiomyopathy as well as noncompaction, aortic root ectasia, and atrial fibrillation, frequent cardiological manifestations of mitochondrial disorders [2], may go subclinical for years [3]. Ventricular runs may remain asymptomatic when occurring during the night. Were cardiac abnormalities reported in any of the affected/unaffected family members? Stroke-like episodes (SLEs) have a variable clinical presentation [4]. How did they manifest clinically in the presented patient? Did they also manifest with seizures? In which cerebral region did equivalent stroke-like-lesions occur? Which type of treatment was provided for SLEs? Did the frequency of SLEs decline after initiation of the vitamin-cocktail? Which remnants of the stroke-like-lesions were seen on MRI? Topiramate is an inhibitor of the mitochondrial carboanhydrase-VB. Topiramate has beneficial [5] and unfavourable effects [6] to mitochondria. As an inhibitor of the mitochondrial transition pore it has an anti-obesity effect but can be also effective in migraine and epilepsy. Did the patient suffer from migraine, a frequent phenotypic manifestation of mtDNA mutations, and did migraine respond to topiramate? Why did she require two antiepileptic drugs in a relatively low dosage? Was reduced weight (35.7 kg at age 15 y) a side effect of topiramate? The patient presented with clinical manifestations of KSS [1]. Which were the clinical manifestations of KSS? Was there an AV-block-III? Did she require a pacemaker? Was CSF protein elevated? Overall, this interesting case report requires a detailed description of the phenotype, a more comprehensive cardiologic investigation, and an explanation of the antiepileptic regimen.
  6 in total

1.  Barth syndrome diagnosed in the subclinical stage of heart failure based on the presence of lipid storage myopathy and isolated noncompaction of the ventricular myocardium.

Authors:  Atsuhito Takeda; Akira Sudo; Masafumi Yamada; Hirokuni Yamazawa; Gaku Izumi; Ichizo Nishino; Tadashi Ariga
Journal:  Eur J Pediatr       Date:  2011-09-20       Impact factor: 3.183

2.  Neuroprotective effects of various doses of topiramate against methylphenidate induced oxidative stress and inflammation in rat isolated hippocampus.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Behnaz Shabab
Journal:  Clin Exp Pharmacol Physiol       Date:  2016-03       Impact factor: 2.557

Review 3.  Cardiac manifestations of primary mitochondrial disorders.

Authors:  Josef Finsterer; Sonam Kothari
Journal:  Int J Cardiol       Date:  2014-11-05       Impact factor: 4.164

4.  Topiramate and visual loss in a patient carrying a Leber hereditary optic neuropathy mutation.

Authors:  Steno Rinalduzzi; Anna Maria Cipriani; Neri Accornero
Journal:  Neurol Sci       Date:  2011-09-07       Impact factor: 3.307

5.  Stroke and Stroke-like Episodes in Muscle Disease.

Authors:  Josef Finsterer
Journal:  Open Neurol J       Date:  2012-05-18

6.  The expanding phenotype of MELAS caused by the m.3291T > C mutation in the MT-TL1 gene.

Authors:  E Keilland; C A Rupar; Asuri N Prasad; K Y Tay; A Downie; C Prasad
Journal:  Mol Genet Metab Rep       Date:  2016-02-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.